Welcome to Xention
Xention is developing novel therapies for the treatment of atrial fibrillation.
The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.
Xention Limited, announced today the launch of Metrion Biosciences, a contract screening business focused on providing comprehensive and high quality ion channel services to the pharma and biotech industry.
Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation
Xention awarded £1.4m from Technology Strategy Board to develop new medicines for atrial fibrillation